at-bcm main investors, LLC

6 east 39th street, 6th floor
attn:lawrence j. studnicky iii
new york, new york 10016

NYS Entity Status
ACTIVE

NYS Filing Date
SEPTEMBER 26, 2013

NYS DOS ID#
4464713

County
NEW YORK

Jurisdiction
DELAWARE

Registered Agent
NONE

NYS Entity Type
FOREIGN LIMITED LIABILITY COMPANY

Name History
2013 - AT-BCM MAIN INVESTORS, LLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • The Top 10 Moments of New York Fashion Week
    By THE NEW YORK TIMES - Friday Sep 15, 2017

    Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.

    Source: NYT > Home Page
  • Women of Sex Tech, Unite
    By ANNA NORTH - Friday Aug 18, 2017

    New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.

    Source: NYT > Home Page
  • Private Equity Investors Have $740 Billion to Spend, Driving Valuations
    By Benjamin Romano - Thursday Aug 17, 2017

    Private equity investors have more capital at their disposal than at any time in more than a decade, which could boost prices for companies seeking acquisitions. As of Aug. 1, private equity firms in North America and Europe had secured $212.6 billion in new commitments this year, on pace to eclipse the “already stellar” fundraising […]

    Source: Xconomy New York
  • IFM Gets $300M Bristol Buyout, Plans Second Strike With New Spinout
    By Ben Fidler - Thursday Aug 3, 2017

    Bristol-Myers Squibb this afternoon is acquiring a young startup, IFM Therapeutics, in an unusual deal that will also see the big drugmaker get a chance to own rights in a new company the biotech is spinning out as well. New York-based Bristol (NYSE: BMY) will pay $300 million up front for IFM, which will give […]

    Source: Xconomy New York
  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
atbcm main investors llc new york ny